Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,632 signal articles · 29 in last 24h · 155,714 total before filter · latest 1h ago
29last 24h
849last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings106M&A122Regulatory20Product21Analyst19
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Duolingo shares rise 3.8% after Evercore ISI upgrade
InvestorsHub25d agobullish
Duolingo shares rise 3.8% after Evercore ISI upgrade

Duolingo (NASDAQ:DUOL) shares rose 3. 8% in pre-market trading after Evercore ISI analyst Mark Mahaney upgraded the stock to “Outperform” from “In Line” and raised the firm’s price target to $210.

1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
StockStory25d agobullish
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Strategy Restarts Bitcoin Buying With 4,603 BTC Acquisition
99bitcoins25d agobullish
Strategy Restarts Bitcoin Buying With 4,603 BTC Acquisition

Strategy has made its first bitcoin purchase in two months, acquiring 4,603 BTC for $369.7 million at an average price of $80,318 per coin, according to a Monday morning press release from the company. The purchase lifts Strategy’s total holdings to 845,050 BTC and ends a buying pause. The mechanics ...

Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
Insider Monkey25d agobullish
Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]